HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)
Agency
National Institutes of Health
Posted
Oct 1, 2026
Due Date
Sep 7, 2027
Description
<p>This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award to support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies. The R61 phase will support the development, refinement, adaptation, and pilot testing of novel or enhanced HIV prevention and treatment strategies, including studies designed to address key scientific, operational, or implementation questions necessary to establish feasibility and readiness for larger-scale evaluation. Projects may generate evidence needed to optimize intervention design, delivery, and implementation in diverse populations and settings. The R33 phase will support expanded testing of interventions and implementation strategies that have successfully met R61 milestones. Studies may evaluate effectiveness, implementation, scalability, sustainability, clinical management, or delivery of HIV prevention interventions that include integrated approaches addressing alcohol use and related comorbidities.</p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 364013
- Solicitation Number
- PAS-28-073
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health